Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of self-administered subcutaneous selatogrel for suspected recurrent acute myocardial infarction after recent myocardial infarction
MOH_2021-08-03_010120Phase 3Recruiting
- Sponsor
- Viatris
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in myocardial infarction (MI) comparing Selatogrel with Placebo (2 arms). Started Jun 2021; status: recruiting.
02
Drugs
selatogrel
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on MOH_2021-08-03_010120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-08-03_010120.